Documente Academic
Documente Profesional
Documente Cultură
Discover
Nephrology Nursing
Diabetes Mellitus
Glomerularnephritis
Interstitial nephritis
Chronic pyelonephritis Hypertension
Vasculitis
Obstructive disorders Hereditary disease
Congenital disorders
Cystic disease
The Kidney
The kidneys weigh about 1/2 pound each.
They are located in the retroperitoneal space. They are about the size of an adult fist They are shaped like a kidney bean. They are attached to the blood stream through the renal arteries.
Nephrons
History of Dialysis
1913 Artificial kidney used in animals. 1935 Heparin purified. 1942 First patient treated with dialysis machine. 1950s Hemodialysis used to treat acute renal failure. 1960 External arteriovenous shunt developed by Drs. Scribner and Quinton. 1965 Internal arteriovenous fistula developed by Drs. Brescia and Cimino. 1972 Medicare ESRD Program established. 1989 - Recombinant human erythropoietin (Epogen) approved by the FDA.
History of Dialysis
1913 Artificial kidney used in animals. 1935 Heparin purified. 1942 First patient treated with dialysis machine. 1950s Hemodialysis used to treat acute renal failure. 1960 External arteriovenous shunt developed by Drs. Scribner and Quinton. 1965 Internal arteriovenous fistula developed by Drs. Brescia and Cimino. 1972 Medicare ESRD Program established. 1989 Recombinant human erythropoietin (Epogen) approved by the FDA.
Basic Treatment
Hemodialysis removes solutes (waste particles) and fluid from the blood across a semipermeable membrane in a filter (dialyzer).
Medication regimens.
Rehabilitation services. Community services.
Social support.
Prevention:
If the patient experiences nausea and vomiting, report this to the dialysis staff prior to dialysis treatment. Communicate with the dialysis staff if the patient goes to dialysis wearing a nitroglycerin patch.
Prevention:
If the patient experiences nausea and vomiting, report this to the dialysis staff prior to dialysis treatment. Communicate with the dialysis staff if the patient goes to dialysis wearing a nitroglycerin patch.
Prevention:
If the patient experiences nausea and vomiting, report this to the dialysis staff prior to dialysis treatment. Communicate with the dialysis staff if the patient goes to dialysis wearing a nitroglycerin patch.
Headaches
Leg cramps
Skin integrity
Hyperglycemia
Symptoms: Causes: Extreme thirst, nausea, blurred vision. Too much concentrated sweets not enough insulin.
Treatment:
Hyperglycemia
Symptoms: Causes: Extreme thirst, nausea, blurred vision. Too much concentrated sweets not enough insulin.
Treatment:
External
Catheter
Bovine
Vectra
Palpation of Access
Thrill +/-
Heat
Drainage Swelling Tenderness
Auscultation of Access
Bruit +/ Quality/character
Post-Dialysis Care
Observe for bleeding from cannulation sites. Hold pressure if necessary. If not controlled, immediately notify the nephrologist and continue to hold pressure. Remove tape/bandage within 24hrs after dialysis.
Typical Medications
Vitamins Multivitamins without minerals or vitamin D Phosphate binders
Erythropoietin
Iron Vitamin D Antihypertensives
Typical Medications
Vitamins Multivitamins without minerals or vitamin D Phosphate binders
Erythropoietin
Iron Vitamin D Antihypertensives
Nutrition
Nutrition plays a critical role in the management of the CKD patient. The diet will vary depending on the type of disease, the CKD stage, and the type of treatment chosen.
Dietary Considerations
PROTEIN POTASSIUM 1.0-1.2g/kg/day 50% high biologic value 40-70 mEq (1500-2500mg)/day
SODIUM
CALORIES FLUIDS
750-1000 mg/day
PHOSPHORUS 600-1200 mg/day >35 kcal/kg/day 1 to 1.5 liters/day plus urine output
Dietary Considerations
PROTEIN POTASSIUM 1.0-1.2g/kg/day 50% high biologic value 40-70 mEq (1500-2500mg)/day
SODIUM
CALORIES FLUIDS
750-1000 mg/day
PHOSPHORUS 600-1200 mg/day >35 kcal/kg/day 1 to 1.5 liters/day plus urine output
Social Services
Social services are provided to patients and their families and are directed at supporting and maximizing the social functioning and adjustment of the patient.
Capacity to control
Helplessness
Family Issues
Financial Concerns
End-of-Life Issues
Assess patient for support systems, emotional status, and perceived quality of life.
Communication
Treatment Communication Long-Term Care Plan Short-Term Care Plan
Low
High
101 mg/dL 14.2 mg/dL 160mg/dL 5.5 mEq/L
Calcium
Phosphorus Glucose Albumin Hemoglobin Hematocrit
9mg/dL
4.5 mg/dL 70 mg/dL 3.5 mg/dL 11g/dL 33%
11 mg/dL
5.5 mEq/L 110 mg 5.0 mg/dL 13 g/dL 39% (if anemic)
Hepatitis Status
Residual Renal Function
Low
High
101 mg/dL 14.2 mg/dL 160mg/dL 5.5 mEq/L
Calcium
Phosphorus Glucose Albumin Hemoglobin Hematocrit
9mg/dL
4.5 mg/dL 70 mg/dL 3.5 mg/dL 11g/dL 33%
11 mg/dL
5.5 mEq/L 110 mg 5.0 mg/dL 13 g/dL 39% (if anemic)
Hepatitis Status
Residual Renal Function
Low
High
101 mg/dL 14.2 mg/dL 160mg/dL 5.5 mEq/L
Calcium
Phosphorus Glucose Albumin Hemoglobin Hematocrit
9mg/dL
4.5 mg/dL 70 mg/dL 3.5 mg/dL 11g/dL 33%
11 mg/dL
5.5 mEq/L 110 mg 5.0 mg/dL 13 g/dL 39% (if anemic)
Hepatitis Status
Residual Renal Function
Low
High
101 mg/dL 14.2 mg/dL 160mg/dL 5.5 mEq/L
Calcium
Phosphorus Glucose Albumin Hemoglobin Hematocrit
9mg/dL
4.5 mg/dL 70 mg/dL 3.5 mg/dL 11g/dL 33%
11 mg/dL
5.5 mEq/L 110 mg 5.0 mg/dL 13 g/dL 39% (if anemic)
Hepatitis Status
Residual Renal Function
References
Gutch,C.F., et al. (1999). Hemodialysis for nurses and dialysis personnel (6th ed.). St. Louis, MO: Mosby, Inc. McCann, L. (1997). Pocket guide to nutrition assessment of the renal patient (2nd ed.) (pp. 9-15). New York: The National Kidney Foundation on Renal Nutrition. National Kidney Foundation. (2003). Kidney disease outcome quality initiative. USRDS. (2001).
U.S. Renal Data System. (2003). USRDS 2003 annual data report: Atlas of end-stage renal disease in the United States. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
Youngerman-Cole, S. (2003). End-stage renal disease. Boise, ID: Healthwise, Inc. Retrieved September 9, 2003, from http://yalenewhavenhealth.org/library/healthguide/en-us/ support/topic.asp?hwid=aa106246
Glossary
Artificial Kidney (Dialyzer) A device that allows for purification of the blood. During the dialysis treatment, blood and dialysate flow through the dialyzer separated by a semipermeable membrane. The pores in the membrane allow the removal of waste products and excess fluid. Dialysate (Bath) Fluid consisting of treated water, electrolytes, and buffers that can be mixed to the individual patient needs. It passes through the dialyzer to remove waste products and excess water. Diffusion The movement of a substance from an area of high concentration to an area of low concentration. Diffusion is the main transport principle for solute (waste products) in hemodialysis Dry weight The weight a patient is estimated to have with normal blood pressure and no fluid retention. Fistula A surgically created connection between a patients own artery and vein. Graft An implant connecting an artery and a vein. Heparin A drug used in the dialysis treatment to prevent clotting of blood in the dialyzer.
Waste Products Substances formed from the breakdown of proteins, nutrients, etc (urea, creatinine).